BI: Extended-release Viramune XR works as well as predecessor

VIENNA A once-daily formulation of an HIV drug made by Boehringer Ingelheim works as well as the twice-daily version, according to results of a study presented Thursday at the 18th annual International AIDS Conference in Vienna.

BI presented results of the VERxVE study, showing that extended-release Viramune XR (nevirapine) worked as well as immediate-release Viramune IR through the 48 weeks of the study.

The drug was effective across patient profiles and did not produce any identifiable new side effects.

Login or Register to post a comment.